Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CD5 CAR-T Cells for Relapsed or Refractory Mature T-Cell Lymphomas
NCT07022964Phase 2Recruiting
- Sponsor
- Beijing Gaobo Hospital
- Start
- Jun 2025
- Primary completion
- Nov 2026
- Modality
- Autologous CAR-T
- Countries
- 1
01
Overview
A Phase 2 trial of CD5 CAR-T cells in T-cell lymphoma, sponsored by Beijing Gaobo Hospital. Started Jun 2025; status: recruiting.
02
Drugs
CD5 CAR-T cells
03
Conditions
T-cell lymphoma
Beyond the preview
Go deeper on NCT07022964.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07022964.